A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT06395519
This study is recruiting at 14 US sites in 13 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced or Metastatic Solid Tumors
- Breast Cancer
- Ovarian Cancer
- Prostate Cancer
- Epithelial Ovarian Cancer
- BRCA2 Mutation
- ER+ Breast Cancer
- Castrate Resistant Prostate Cancer
- BRCA1 Mutation
- BRCA Mutation
- Endometrial Cancer
- Colorectal Cancer
- Gastric Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- 858 Therapeutics, Inc.
- Last updated on ClinicalTrials.gov
- March 27, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Mayo Clinic · Phoenix, AZ
Connecticut · 1
- Yale University, Yale Cancer Center · New Haven, CT
Florida · 1
- Mayo Clinic · Jacksonville, FL
Illinois · 1
- University of Chicago Medical Center · Chicago, IL
Massachusetts · 1
- Massachusetts General Hospital · Boston, MA
Minnesota · 1
- Mayo Clinic · Rochester, MN
New York · 2
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health · New York, NY
- Memorial Sloan Kettering Cancer Center · New York, NY
Ohio · 1
- Stefanie Spielman Comprehensive Breast Center · Columbus, OH
Pennsylvania · 1
- Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center · Philadelphia, PA
Texas · 1
- MD Anderson Cancer Center · Houston, TX
Utah · 1
- START Center for Cancer Care - Mountain Region · Salt Lake City, UT
Virginia · 1
- Virginia Cancer Specialists · Fairfax, VA
Washington · 1
- Fred Hutchinson Cancer Center · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.